We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Combination of Gene Mutations Linked to Endometrial Cancer

By LabMedica International staff writers
Posted on 21 Aug 2019
Print article
Image: The NextSeq 500 next-generation sequencer (Photo courtesy of Illumina).
Image: The NextSeq 500 next-generation sequencer (Photo courtesy of Illumina).
The endometrium is the dynamic inner layer of the uterus, composed of stroma and epithelial cells that undergo monthly proliferation, differentiation, and shedding throughout the menstrual cycle in reproductive age women.

An estimated 63,230 women will be diagnosed with endometrial cancer (EC) this year. Disruption of normal endometrial processes results in a number of pathologies, including endometrial hyperplasia, EC, endometriosis, adenomyosis, and endometriosis-associated ovarian cancer (EAOC).

Gynecologists and their colleagues at Michigan State University (Grand Rapids, MI, USA) identified a combination of two gene mutations that are linked to endometrial cancer. They found that mutations of the AT-Rich Interaction Domain 1A (ARID1A) and the Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) genes are frequently found together in the development of EC, as well as in EAOC. The team analyzed the samples with a next-generation sequencer, the NextSeq 500, a machine that rapidly sequences the human genome.

ARID1A is a tumor suppressor. When it mutates, chromatin, cellular material that keeps DNA compacted in cells, loses its structure, allowing cancer to spread. PIK3CA is an instructional gene that tells the body to produce certain proteins and leads to uncontrolled growth of cells when it mutates. Similarly, these same mutations often are found in women who have endometriosis, a painful condition in which uterine tissue grows outside the uterus, but many of those affected never develop endometrial cancer.

Ronald L. Chandler, PhD, an assistant professor of obstetrics, gynecology and reproductive biology, and corresponding author of the study, said, “We're trying to understand why some women with the same set of mutations get cancer and some don't. There is something else involved. The hardest part of our job is figuring out what's causing it. Is it something in the environment or it is something else? It's a complex process. These are big questions that we're trying to address.” The study was published on August 7, 2019, in the journal Nature Communications.

Related Links:
Michigan State University

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.